Skip to content
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Blog
Commitment to Quality
Press Releases
Events
All Events
Access! 2027
GRx+Biosims 2027
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Blog
Commitment to Quality
Press Releases
Events
All Events
Access! 2027
GRx+Biosims 2027
JOIN
SEARCH
Home
Blog
Biosimilars Council Press Releases
Blog
Blog
November 4, 2026
AAM
GRx+Biosims 2026: Resilience, Reinvigoration, and Rock n’ Roll in Rockville
Blog
November 3, 2026
AAM
Chain Reactions: Strategies to Bolster America’s Supply of Critical Medicines
Blog
November 2, 2026
AAM
Trust But Verify, Verify, Verify
Blog
October 13, 2026
AAM
Estrogen Patches: How Generic Manufacturers Have Ramped Up Production
Blog
October 8, 2026
AAM
For Policy, Regulatory, Legal and Scientific Professionals, GRx+Biosims is a MUST Attend
Blog
October 7, 2026
AAM
Putting Generics and Biosimilars First: Sustaining the Cornerstone of Affordable Healthcare in the US
Blog
July 28, 2026
AAM
The Numbers Don’t Lie: Drug Shortages Remain a Systemic Threat to Patients
Blog
February 25, 2026
AAM
ACCESS! 2026 Day 2 Recap
Blog
February 25, 2026
AAM
Meet the New AAM Board Chair: Bob Hoffman
Blog
February 24, 2026
AAM
ACCESS! 2026 Day 1 Recap
Blog
October 29, 2025
AAM
GRx+Biosims 2025 Day 3 Recap: Passion Manifests In Progress
Blog
October 28, 2025
AAM
GRx+Biosims 2025 Day 2 Recap: From Passion to Progress
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2027
GRx+Biosims 2027
Press Releases
JOIN
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
PBM Reform
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Blog
Commitment to Quality
Press Releases
Events
All Events
Access! 2027
GRx+Biosims 2027
JOIN
SEARCH